There are two issues. First, we want to be sure that use of any treatment that we offer in the NHS is evidence-based and will do patients some good. That is not the case just for Lyme disease, but for any condition. Clinicians rely on international experience and evidence. We have the benefit of the National Institute for Health and Care Excellence, which is United Kingdom based, but there is also the European Centre for Disease Prevention and Control and the Centers for Disease Control and Prevention in North America, where Lyme disease was first recognised and there is a huge amount of Lyme disease.
There is a large body of international evidence on treatments and what best can be done for patients who are suffering. In particular, longer-term antibiotic treatment has been looked at. Very commonly, patients with Lyme disease ask me whether it will do them any good to have antibiotics for a month or two, or six months. The evidence is that it would not. There have been a number of large trials including blind comparison of patients who had antibiotics with patients who had a placebo, so we did not know which group was which. The overwhelming evidence in those trials is that the longer-term antibiotics did not offer anything better than the placebo. Both groups showed improvement, but there was no difference based on whether the patients had had antibiotics. Certainly, from my perspective and those of my clinicians, that treatment is not justified based on the available evidence.
That is not to say that there will not be evidence in the future to support such treatment; we always keep an open mind. We would not give patients longer-term antibiotics based on the current available evidence. I have seen one of my patients who received longer-term antibiotics having a serious reaction to them, so they are not entirely risk-free. We have to make sure that we strike the right balance between risk and harm.
There is definitely room for improvement in what treatment we offer to people who have longer-term symptoms and who are clearly suffering. We are lacking evidence on that. NICE, the European Centre for Disease Prevention and Control and the Infectious Diseases Society of America guidelines all acknowledge that that is an area in which more research is needed.
That shades into other areas such as chronic fatigue syndrome and, of course, as we have seen recently, patients who are experiencing longer-term symptoms after Covid. Whether those have similar underlying causes and whether treatments will work for all groups and so on, we do not honestly know, so we need better evidence to see how best we can help those people.
Antibiotics and some other treatments that are offered privately are not, to the best of my knowledge, based on evidence, treatments that we can recommend currently. I hope that helps and sets out what we can do and perhaps what we need to know. Perhaps Gill Hawkins wants to add something from the public health perspective.
09:45